MedTrace Logo

Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

NCT06455046 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2024-06-12

No results posted yet for this study

Summary

In order to improve the clinical effect and find a new safe and effective treatment model for advanced recurrent cervical cancer, this study explored the efficacy level safety of pemetrexed, carboplatin, recombinant human adenovirus type 5, and AK104 regimen in recurrent and refractory advanced cervical cancer. For some patients with immune-resistant cervical cancer, combination chemotherapy and oncolytic virus therapy can promote the transformation of cold tumors into hot tumors, eliminate and then reverse the suppressor factors of immune resistance, and break the dilemma of immunotherapy drug resistance, which is a new method and strategy under immunotherapy drug resistance.

Conditions

  • Cervical Cancer Recurrent

Interventions

DRUG

AK104

PD-1/CTLA-4 bispecific antibody

DRUG

Recombinant Human Adenovirus 5 Injection

Recombinant Human Adenovirus 5 Injection

Sponsors & Collaborators

  • Zhangzhou Municipal Hospital of Fujian Province

    collaborator OTHER

  • Fujian Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Qin Xu · Fujian Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-11
Primary Completion
2025-10-10
Completion
2025-10-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06455046 on ClinicalTrials.gov